Dr. Sokolova on the significance of genetic testing in prostate cancer
Alexandra Sokolova, MD, explains the importance of genetic testing for patients with high-risk localized and advanced prostate cancer, as well as for their high-risk family members.
In this video, Alexandra Sokolova, MD, assistant professor of medicine, Division of Hematology/Medical Oncology, School of Medicine, Oregon Health & Science University, discusses the importance of genetic testing in patients with prostate cancer and those at high risk of developing prostate cancer.
Transcript
Genetic testing is significant for men with prostate cancer. Germline testing is now recommended for all men with high-risk localized prostate cancer and all men with metastatic prostate cancer, along with men who meet family history criteria, who should also be considered. I think it's really important to test those men early and identify them early so we can provide them with the best care. It's also important to tell their family members so we can identify those family members who carry the same germline mutation in order to detect cancer early and do some cancer prevention strategy for both men and women. And as we think about moving forward to the prostate cancer genetics field, I think it's important to really identify those men with germline mutations who are at high risk of developing prostate cancer before they have prostate cancer. So through cascade testing, for example, we can determine who is at a higher risk of having a prostate cancer, so we can identify those cancers early and treat them very aggressively with a goal of cure.
Transcript has been edited for clarity.
Prostate cancer genomic tests show prognostic value for progression, therapy benefit
April 22nd 2024"This preplanned ENACT trial biomarker analysis demonstrates the value of the Decipher score, AR-A score, and PAM50 genomic classifiers in identifying patients undergoing AS who are most likely to benefit from enzalutamide treatment," wrote the authors.
Personalized therapeutic approaches in ccRCC remain challenging
April 15th 2024"As a kidney cancer community, we need to investigate these molecular subtypes prospectively in clinical trials to determine whether specific subtypes benefit from certain therapies or not," says David A. Braun, MD, PhD.
Dr. Xu on why biomarkers are needed for individualized treatment approaches in RCC
April 5th 2024“Systemic therapy for RCC has changed very quickly. Every year, it's exciting to see that we're getting new developments, new drug approvals, and changes in the standard of care,” says Wenxin (Vincent) Xu, MD.
